Reprosci Biosciences launched its flagship multi-award-winning medical training simulator for Assisted Reproductive Technology (ART) Procedures-the FERTILATOR, in India during the 10th Edition of Lifesciences & Healthcare Innovation Forum (LHIF)

Reprosci Biosciences is a full-stack reproductive health sciences startup built with the vision of bringing certainty to fertility care. The founding Directors of Reprosci include Dr Ravi S Swamy, a Clinician & Researcher from Imperial College Healthcare (NHS Trust, U.K.) and Dr Mahendra Narwaria, a leading Surgeon-Healthcare entrepreneur from Ahmedabad, India.

In two decades, the world has seen an alarming increase in infertility cases from under 2% to over 20% resulting in the need for a ten-fold increase in the specialists who would cater to the needs of the global marketplace. Alongside the shortage of skilled healthcare professionals, the dismal live-birth rate is another issue that needs immediate attention.

With the vision to transform reproductive and family health, Reprosci Biosciences has set on a mission to empower a million healthcare professionals through its metaverse training platform and ten million couples through personalized biotherapeutics. The company is transitioning from seven years of R&D to commercialization.

Based and incubated at the Center of Excellence, Bengaluru, which is a Joint initiative of the Ministry of Electronics and Information Technology (MeitY), Govt. of Karnataka, and NASSCOM, Reprosci Biosciences is unleashing the potency of Regenerative Medicine & Medical Training Simulation to bring about far-reaching changes in the Clinical Outcomes that support Assisted Reproductive Technology (ART) and Assisted Natural Pregnancy (ANP) based treatments.

The India launch of Fertilator at LHIF was hosted by the K-tech Centre of Excellence IoT & AI, Bengaluru (an initiative of MeitY and KITS) on 20th July 2022. Reprosci showcased Fertilator in Milan, Italy, at the European Society of Human Reproduction and Embryology (ESHRE) Congress 2022, which was attended by nearly 11,000 Infertologists, Gynaecologists & Embryologists from over 140 Countries.

Their breakthrough Innovation BAP.C 2.0 is an autologous biotherapeutic for reproductive regeneration. BAP.C has been, to date, administered to over 4500 Women with a regeneration rate of 88.6% and pregnancy rate of 48.6%. It is a regenerative growth factor and protein concoction derived from the patient’s blood. This regenerative formulation has zero side-effects protocols that span the spectrum of reproductive wellness for both male and female infertility conditions. It increases the possibility of pregnancy in IVF procedures, promotes the natural proliferation of stromal and epithelial cells, accelerates tissue regeneration & remodelling, and essentially restores the effective functioning of the reproductive system, significantly enhancing the chance of pregnancy.

Reprosci has been a commercial vehicle for research for over seven years. It has finalized a significant strategic investment from doctors in India and the U.K. Creating a coterie of advisers and medical experts to empower couples in this transition to parenthood remains the sole objective of Reprosci Biosciences. The startup is making its way into the Metaverse world. It intends to develop unparalleled innovation using its associated Virtual Communities of Practice (vCoP) platform, Fertilator, and the most trending technology today- Metaverse for enhancing Reproductive Health, Sexual Wellness & Infertility Care.

It aims to aid 10 million couples in achieving parenthood. It resolves to enable Infertologist to achieve Mastery in Assisted Reproduction Technology (ART) procedures by leveraging its exclusive Medical Training Simulator, i.e. Fertilator.

“NASSCOM CoE has been enabling strategic partnerships with leading Pharmaceutical & Medical Technology Companies to help accelerate the growth of the high-potential startup which can transform humanity. NASSCOM has also been facilitating international alliances. With this support, Reprosci is set to expand to Europe soon to be able to cater to the World with its toted Indian Innovation, i.e., Fertilator,” Dr Ravi S Swamy, a Clinician & Researcher from Imperial College Healthcare (NHS Trust, U.K.).